| John Harold Ball, PA-C | |
|
395 W Bulldog Blvd Ste 401, Provo, UT 84604-3338 | |
| (801) 357-7546 | |
| (801) 357-8840 |
| Full Name | John Harold Ball |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 30 Years |
| Location | 395 W Bulldog Blvd Ste 401, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003975145 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 349321-1206 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
URAC today announced a call for public comment on the second set of toolkits for its new Patient Centered Health Care Home (PCHCH) Program. The program, comprised of an integrated series of three educational toolkits, will help health care practices follow a step-wise process in their journey to becoming a PCHCH.
3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
With over 120,000 patients in the United States waiting for a kidney transplant, scientists and physicians are constantly looking to expand the pool of available organs through increasing donation and optimizing allocation.
The American Medical Society for Sports Medicine and its Collaborative Research Network are pleased to announce the recipients of a $300,000 research grant, made possible by Avanos Medical, to study the treatment of musculoskeletal conditions using cooled radiofrequency ablation (CRFA) technology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Harold Ball, PA-C 395 W Bulldog Blvd Ste 401, Provo, UT 84604-3338 Ph: (801) 357-7546 | John Harold Ball, PA-C 395 W Bulldog Blvd Ste 401, Provo, UT 84604-3338 Ph: (801) 357-7546 |
News Archive
URAC today announced a call for public comment on the second set of toolkits for its new Patient Centered Health Care Home (PCHCH) Program. The program, comprised of an integrated series of three educational toolkits, will help health care practices follow a step-wise process in their journey to becoming a PCHCH.
3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
With over 120,000 patients in the United States waiting for a kidney transplant, scientists and physicians are constantly looking to expand the pool of available organs through increasing donation and optimizing allocation.
The American Medical Society for Sports Medicine and its Collaborative Research Network are pleased to announce the recipients of a $300,000 research grant, made possible by Avanos Medical, to study the treatment of musculoskeletal conditions using cooled radiofrequency ablation (CRFA) technology.
› Verified 5 days ago
Kelly Marie Daly-wolfe, PA-C, RDN Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 589 S State St, Provo, UT 84606 Phone: 801-429-2000 | |
Devin W Christensen, PA-S2 Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1360 S 760 W, Provo, UT 84601 Phone: 801-471-7998 | |
Joan Margaret Butler, Physician Assistant Medicare: Medicare Enrolled Practice Location: 750 N Freedom Blvd, Provo, UT 84601 Phone: 801-373-4760 | |
Robert Rowe, Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 589 S State St, Provo, UT 84606 Phone: 801-429-2000 | |
Michael Anderson, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1055 N 500 W Ste 101, Provo, UT 84604 Phone: 801-373-4366 Fax: 801-418-0941 | |
Stacie Glass, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 395 W Cougar Blvd Ste 602, Provo, UT 84604 Phone: 801-357-0570 |